Xylitol for C. Difficile
Trial Summary
What is the purpose of this trial?
This 3+3 dose escalation pilot trial will assess the safety and efficacy of xylitol as an oral therapeutic for decolonization of C. difficile in the Inflammatory Bowel Disease (IBD) patient population.
Will I have to stop taking my current medications?
The trial does not specify if you need to stop taking your current medications, but it does exclude those who are on chronic antibiotics.
What data supports the effectiveness of the treatment Xylitol for C. Difficile?
Is xylitol safe for humans?
How does the treatment Xylitol differ from other treatments for C. difficile infection?
Research Team
Jessica Allegretti, MD MPH
Principal Investigator
Brigham and Women's Hospital
Eligibility Criteria
This trial is for adults over 18 with Inflammatory Bowel Disease (IBD) who are coming in for a colonoscopy or clinic visit. They should have inactive or mild IBD, as shown by specific low disease scores. People can't join if they use antibiotics often, had certain gut surgeries, can't swallow pills, or are allergic to xylitol.Inclusion Criteria
Exclusion Criteria
Timeline
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants receive daily doses of xylitol for 7 days in one of five dosing groups
Follow-up
Participants are monitored for safety, efficacy, and clinical outcomes, including C. difficile decolonization and IBD activity
Treatment Details
Interventions
- Xylitol
Find a Clinic Near You
Who Is Running the Clinical Trial?
Brigham and Women's Hospital
Lead Sponsor